DOUGLAS SEGARS: Open Payments
NPI 1649553165 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 22 payments from 9 companies in 2025. Trend: 2023 $330 · 2024 $487 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $94 |
| Janssen Pharmaceuticals, Inc | 5 | $93 |
| Alkermes, Inc. | 3 | $66 |
| Lundbeck LLC | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| ABBVIE INC. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
Products named: INGREZZA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, COBENFY, VRAYLAR, VIVITROL, ARISTADA, CAPLYTA.
Industry payments across TX — which companies pay providers there.
